Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
Nature Genetics
|
June 28, 2008
ESR1 gene amplification in breast cancer: a common phenomenon?
Lindsay A Brown, Jeremy Hoog, Suet-Feung Chin, et al.
Cancer Discovery
|
August 13, 2017
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Svasti Haricharan, Nindo Punturi, Purba Singh, et al.
Nature Communications
|
August 10, 2016
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
Christopher A Miller, Yevgeniy Gindin, Charles Lu, et al.
NPJ Breast Cancer
|
January 7, 2023
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)
Foluso O Ademuyiwa, Donald W Northfelt, Tracey O'Connor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2011
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031
Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Nature
|
August 17, 2017
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel, Molly J DeCristo, April C Watt, et al.
Cancer Immunology Research
|
June 17, 2017
Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor Immunity
Xiuli Zhang, Samuel Kim, Jasreet Hundal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 4, 2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer
Cynthia X Ma, Feng Gao, Jingqin Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer
Cynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
Nature Genetics
|
June 28, 2008
ESR1 gene amplification in breast cancer: a common phenomenon?
Lindsay A Brown, Jeremy Hoog, Suet-Feung Chin, et al.
Cancer Discovery
|
August 13, 2017
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Svasti Haricharan, Nindo Punturi, Purba Singh, et al.
Nature Communications
|
August 10, 2016
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
Christopher A Miller, Yevgeniy Gindin, Charles Lu, et al.
NPJ Breast Cancer
|
January 7, 2023
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)
Foluso O Ademuyiwa, Donald W Northfelt, Tracey O'Connor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2011
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031
Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Nature
|
August 17, 2017
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel, Molly J DeCristo, April C Watt, et al.
Cancer Immunology Research
|
June 17, 2017
Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor Immunity
Xiuli Zhang, Samuel Kim, Jasreet Hundal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 4, 2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer
Cynthia X Ma, Feng Gao, Jingqin Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer
Cynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Page
of 5